Search

Meeting Coverage:

American Society of Cataract and Refractive Surgery Meeting

ASCRS: 2024

Punctal Occlusion With Lacrifill

Eric Donnenfeld, MD

Show Description +

Eric Donnenfeld, MD, discusses Lacrifill Canalicular Gel (Nordic Pharma), a crosslinked hyaluronic acid derivative that is FDA-cleared to temporarily block tear drainage by the occlusion of the canalicular system. He highlighted outcomes from the FDA trial during the ASCRS annual meeting in Boston.

Posted: 4/10/2024

Keywords:

Lacrifill Canalicular Gel

•

Nordic Pharma

•

crosslinked hyaluronic acid derivative

Up Next

Cyclosporine 0.09% Treatment Before Cataract Surgery

Cyclosporine 0.09% Treatment Before Cataract Surgery

John Hovanesian, MD

Laser Treatment for Pigmentary Glaucoma

Laser Treatment for Pigmentary Glaucoma

Monica Ertel, MD

Innovations and Challenges in Glaucoma Management

Innovations and Challenges in Glaucoma Management

Leon Herndon, MD

Surgical Innovations in Keratoconus

Surgical Innovations in Keratoconus

Brandon Ayres, MD

Uveitis in Glaucoma

Uveitis in Glaucoma

Erin Sieck, MD

Implementing New Innovations in AI and Telemedicine

Implementing New Innovations in AI and Telemedicine

Grayson Armstrong, MD, MPH

ABCs and LCDs of MIGS

ABCs and LCDs of MIGS

Parag Parekh, MD

$Maximizing Refractive Outcomes in Cataract and Glaucoma Surgery$

Maximizing Refractive Outcomes in Cataract and Glaucoma Surgery

Brandon Baartman, MD

Presbyopia Drops

Presbyopia Drops

Kathryn Hatch, MD

Data Ownership in Ophthalmology

Data Ownership in Ophthalmology

Eric Rosenberg, DO

Revolution in Endothelial Keratoplasty

Revolution in Endothelial Keratoplasty

Winston Chamberlain, MD

ICL Rotation: When and Why?

ICL Rotation: When and Why?

Karolinne Maia Rocha, MD

Next-Generation IOLs: Considerations for Retina Patients

Next-Generation IOLs: Considerations for Retina Patients

Y. Ralph Chu, MD

Advocating for Patients

Advocating for Patients

Patti Barkey

Back to All Videos

Punctal Occlusion With Lacrifill

Eric Donnenfeld, MD

Eric Donnenfeld, MD, discusses Lacrifill Canalicular Gel (Nordic Pharma), a crosslinked hyaluronic acid derivative that is FDA-cleared to temporarily block tear drainage by the occlusion of the canalicular system. He highlighted outcomes from the FDA trial during the ASCRS annual meeting in Boston.

Posted: 4/10/2024

Keywords:

Lacrifill Canalicular Gel

•

Nordic Pharma

•

crosslinked hyaluronic acid derivative

Please log in to leave a comment.

More From ASCRS: 2024 Coverage

Uveitis in Glaucoma

Uveitis in Glaucoma

Erin Sieck, MD

Implementing New Innovations in AI and Telemedicine

Implementing New Innovations in AI and Telemedicine

Grayson Armstrong, MD, MPH

ABCs and LCDs of MIGS

ABCs and LCDs of MIGS

Parag Parekh, MD

$Maximizing Refractive Outcomes in Cataract and Glaucoma Surgery$

Maximizing Refractive Outcomes in Cataract and Glaucoma Surgery

Brandon Baartman, MD

Bryn Mawr Communications, LLC, and Eyetube.net are not affiliated with the official program of ASCRS: 2024.